Welcome to our dedicated page for Ironwood Pharmaceuticals news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals stock.
Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Summary not available.
Summary not available.
Ironwood Pharmaceuticals (Nasdaq: IRWD) has authorized a new share repurchase program allowing for the buyback of up to $150 million of its outstanding shares through December 2022. This initiative reflects Ironwood's disciplined capital allocation strategy and confidence in its financial position. The company aims to return cash to shareholders while continuing to focus on maximizing revenues from LINZESS® and developing innovative treatments for GI diseases. Management will determine the timing and method of repurchases based on market conditions.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported strong first quarter 2021 results, with total revenues of $88.8 million, up 11% from $79.9 million in Q1 2020. LINZESS prescription demand grew 12% year-over-year, contributing to net sales of $215.4 million. GAAP net income surged to $39.9 million or $0.25 per share, compared to $3.3 million or $0.02 per share last year. Operating expenses decreased significantly to $43.4 million. Ironwood ended Q1 with $438.5 million in cash and cash equivalents, positioning itself well for future investments.
Ironwood Pharmaceuticals (NASDAQ: IRWD) has announced its first quarter 2021 investor update conference call and webcast scheduled for May 6, 2021, at 8:30 a.m. Eastern Time. Interested participants can join by calling (833) 350-1432 for U.S. and Canada, or (647) 689-6932 internationally, using conference ID 8067476. A replay will be available after 11:30 a.m. on the same day until May 20, 2021. Ironwood focuses on developing treatments for gastrointestinal diseases, with linaclotide being a key product for IBS-C and CIC.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will present at three major investor conferences in February and March 2021:
- SVB Leerink Global Healthcare Conference on February 26 at 8:00 a.m. EST
- Cowen Annual Health Care Conference on March 2 at 11:10 a.m. EST
- Barclays Global Healthcare Conference on March 9 at 3:35 p.m. EST
Investors can access live webcasts through the company's website, with replays available for 14 days after each conference. Ironwood specializes in GI-related healthcare, notably its leading treatment for IBS-C and CIC.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its fourth quarter and full year 2020 results, highlighting significant growth in LINZESS net sales, which rose 10% year-over-year despite COVID-19 challenges. Total revenues for the fourth quarter were $116.7 million, down from $126.3 million in 2019, while full-year revenues decreased to $389.5 million from $428.4 million. Despite these declines, Ironwood reported a GAAP net income of $106.2 million for 2020, compared to $21.5 million in 2019. The company anticipates LINZESS net sales growth of 3-5% in 2021.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that Mark Mallon will step down as CEO effective March 12, 2021, to pursue another opportunity. Thomas McCourt, currently president, will become interim CEO. Julie McHugh will serve as executive chair of the Board of Directors. The Board is initiating a search for Mallon's permanent successor. The company emphasizes its commitment to maximizing LINZESS, its leading product for GI diseases, and aims for sustained profitability and growth despite the ongoing challenges from the COVID-19 pandemic.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced their fourth quarter and full year 2020 investor update conference call on February 17, 2021, at 8:30 a.m. Eastern Time. Participants can join via phone or access the webcast on their website. The call will also be available for replay starting the same day at 11:30 a.m. through March 3, 2021. Ironwood, founded in 1998 and headquartered in Boston, specializes in medicines for gastrointestinal (GI) diseases, including linaclotide, a leading treatment for IBS-C and CIC.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 5:20 p.m. ET. The presentation will include a corporate overview and a Q&A session. Interested parties can access a live webcast via Ironwood's website, with a replay available for 14 days post-conference. Ironwood specializes in developing treatments for gastrointestinal diseases, notably linaclotide for IBS-C and CIC, and was founded in 1998, based in Boston.